CompletedPHASE1, PHASE2NCT06329492
Autologous Alpha-2 Macroglobulin Rich Plasma, Safety and Efficacy in Symptomatic Moderate Knee Osteoarthritis
Studying Microphthalmia with limb anomalies
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Brennan Boettcher, D.OMayo Clinic
- Intervention
- Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP)(biological)
- Enrollment
- 20 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2024 – 2026
Study locations (1)
- Mayo Clinic, Rochester, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06329492 on ClinicalTrials.gov